Nuvation Bio (NUVB)
(Delayed Data from NYSE)
$3.71 USD
+0.01 (0.27%)
Updated Oct 2, 2025 04:00 PM ET
After-Market: $3.70 -0.01 (-0.27%) 6:56 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NUVB 3.71 +0.01(0.27%)
Will NUVB be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NUVB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NUVB
Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
NUVB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy
Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates
Other News for NUVB
MACD Bullish Signal Line Cross appears for NUVB after 0.54% move
Is NUVB gaining bullish strength? Crossed Above 20 Day Moving Average shows up after soaring 14.91%
Nuvation Bio (NUVB) Surges 13% Following Phase 3 Enrollment and Buy Rating
NUVB Stock Surges: Key Developments Driving Growth
Nuvation Bio up after enrollment update, Jefferies’ bullish view